The best indicator for MetLife (MET)
We backtested 20 indicators across daily, weekly and hourly charts on real MetLife (MET) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Bollinger Mean-Reversion
On the daily chart, this is the strongest risk-adjusted edge we found for MetLife (MET) over ~26.1 years — beating buy-and-hold by 1.7% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Bollinger Mean-Reversion ✓ | Daily | 11.4% | 0.56 | -50.6% | 74.8% | 123 | 1.7% |
| 2 | RSI Mean-Reversion ✓ | Daily | 8.9% | 0.55 | -46.4% | 78.1% | 32 | -0.9% |
| 3 | Stochastic ✓ | Daily | 11.7% | 0.55 | -50.1% | 77.2% | 136 | 2.0% |
| 4 | CCI ✓ | Daily | 9.9% | 0.49 | -58.3% | 71.9% | 139 | 0.2% |
| 5 | Money Flow Index ✓ | Daily | 10.5% | 0.46 | -82.1% | 77.3% | 22 | 0.8% |
| 6 | Williams %R ✓ | Daily | 8.3% | 0.42 | -67.7% | 72.3% | 177 | -1.5% |
| 7 | WaveTrend (8/6/4) ✓ | Daily | 7.3% | 0.39 | -63.6% | 77.6% | 98 | -2.4% |
| 8 | Holy Grail Confluence ✓ | Daily | 6.6% | 0.38 | -63.6% | 83.8% | 37 | -3.1% |
| 9 | Stochastic ✓ | Weekly | 5.5% | 0.33 | -79.3% | 82.6% | 23 | -4.3% |
| 10 | Williams %R ✓ | Weekly | 4.4% | 0.29 | -79.3% | 75.7% | 37 | -5.3% |
| 11 | Bollinger Mean-Reversion ✓ | Weekly | 4.1% | 0.28 | -70.4% | 86.4% | 22 | -5.6% |
| 12 | SMA 50/200 Cross ✓ | Daily | 3.5% | 0.27 | -49.4% | 38.9% | 18 | -6.2% |
| 13 | Heikin-Ashi Trend ✓ | Weekly | 3.5% | 0.26 | -52.7% | 50.0% | 250 | -6.2% |
| 14 | CCI ✓ | Weekly | 2.5% | 0.23 | -79.3% | 77.8% | 27 | -7.2% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For MetLife (MET), Bollinger Mean-Reversion on the daily timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.